Posted on by Newsdesk

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

  • Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,**
  • PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,†
  • Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡

TORONTO–(BUSINESS WIRE)–
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients inCanada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,§,§§,¶,¶¶

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620166312/en/

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,” said Rob Scott, VP, Intraocular Devices, R&D, Alcon. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”1-3,20,21,*,**,‡‡,‖,Ω

“PanOptix has been a cornerstone of my cataract practice for eight years,” said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. “These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile25, ∂and a happy patient with greater spectacle independence.23, § So, it’s exciting to see this technology evolve to further meet patients’ visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.”

PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe® preloaded delivery system and as well as with the Clareon Monarch® IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.22

For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative.

About Clareon PanOptix Pro

The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at ifu.alcon.com.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.

*PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light).

**Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.

†For feasible diffractive optics of up to pentafocal design from Krackhardt et al.

††Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic.

‡Compared to Clareon PanOptix.

‡‡Based on bench and vision simulator studies.

§Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276).

§§All-implanted analysis set.

¶In response to the IOLSAT questionnaire question “In the past 7 days, how often did you need to wear eyeglasses to see”?

¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op “Given your vision today, if you had to do it all over, would you have the same lenses implanted again?”; n=127.

‖Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024.

ΩSeverity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64).

∂Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including “very bothersome” and “severe” visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent.

References

  1. Alcon data on file, 2025. REF-25218

  2. Alcon data on file, 2024. REF-25221

  3. Alcon data on file, 2015. REF-08546

  4. Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.

  5. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston.

  6. Rayner Professional Website. https://rayner.com/en/iol/trifocal/rayone-trifocal/. Accessed September 2024.

  7. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53.

  8. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014.

  9. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; https://europe.ophthalmologytimes.com/zeiss-cataract-insight-series?page=1. Accessed September 2024.

  10. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234.

  11. Alcon data on file, 2024. REF-23958.

  12. Alcon data on file, 2018. REF-01475.

  13. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021.

  14. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965

  15. Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. https://www.ccohs.ca/oshanswers/ergonomics/office/.

  16. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164

  17. Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/j.ajo.2015.09.030

  18. Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/j.jcrs.0000000000000780

  19. Alcon data on file, 2024. REF-25903

  20. Alcon data on file, 2024. REF-23554

  21. MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023.

  22. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use.

  23. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/s40123-023-00657-5.Alcon Vision LLC.

  24. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/j.ophtha.2020.07.015

  25. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.

Connect with us on

Facebook

LinkedIn

Media Relations

Jane Lee Cheung

+1 289 290 2393 (Canada)

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Technology Health Optical

MEDIA:

Photo
Photo
Photo
Photo
Logo
Logo